More than a dozen civil society groups in India have written an open letter to Johnson & Johnson and the U.S. government, urging the pharmaceutical giant to cancel export of Indian-made COVID-19 vaccine doses to rich countries and instead focus on distributing them in the Global South. “The 600 million doses that Johnson & Johnson is manufacturing currently … in India should go where the vaccines are most needed, which is the Indian subcontinent, the African continent and the COVAX Facility,” says public health activist Achal Prabhala, who co-authored the letter and is coordinator of the AccessIBSA project, which campaigns for access to medicines in India, Brazil and South Africa.

This post was originally published on Democracy Now!.